Norris Medicines (524414)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

When I look at Norris Medicines, the first thing I tell myself is: growth is not the same as value. Sales jumped 194.59% and profit grew 350.00%, but those numbers come off a tiny base in an industry—trading and distribution—that almost never offers a durable moat. The quality of the business is poor: ROE is just 0.86%, and ROCE is deeply negative at -10.13%. That means the company is not earning a satisfactory return on either shareholder equity or capital employed. For a trader, those numbers are dangerous. The price is ₹13.07, near the bottom of the ₹12.00-₹19.25 range, and the market cap is only ₹14 crore. With P/E shown as 0.00 and book value N/A, I cannot apply my normal valuation framework. The latest quarter had sales of ₹3 crore and net profit of ₹1 crore—a 33% margin that would be extraordinary for a pure distribution business, so I would immediately question its sustainability. The Piotroski score of 6/9 gives a little comfort that financial health is improving, but a score is not a substitute for a strong balance sheet or pricing power. There is no dividend, promoter holding is not disclosed, and debt/equity is N/A. In Benjamin Graham's language, this is speculative, not investment. If this is a turnaround, it is still unproven. I would need several more quarters of cash profits, improving returns on capital, and transparent ownership before putting this in my portfolio.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer